ClinicalTrials.gg
CompletedNCT05419856LASAREUpdated Jun 26, 2025Results posted

Safety, Tolerability and Pharmacokinetics of Intraarticular 4P004 Single Dose in Patient With KL 2-4 Osteoarthritic Knee

A Phase 1 interventional study of 4P-004 and Placebo in Knee Osteoarthritis, sponsored by 4Moving Biotech. Completed at 3 sites in Belgium. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-06-26.

Sponsored by 4Moving Biotech · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 46 studies in Osteoarthritis, Knee with a site in Belgium — 6 open to participants now, 11 under way, none of them phase 3. Osteoarthritis, Knee · Belgium.

Enrollment
30th of 38
34 · median 86
Started
2022
with 3 others
Phase 1
3 of 46
none open now
Registered
39th of 46
by date
Lead sponsor
1 of 46
4Moving Biotech

Among the 46 studies in Osteoarthritis, Knee with a site in Belgium, this one is the 30th largest by enrollment of the 38 interventional ones that give a count, is one of 4 that started in 2022, is one of 3 in phase 1, and was the 39th registered.

Osteoarthritis, Knee

3,295 studies on the registry are indexed under Osteoarthritis, Knee; 624 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

6 of the 46 studies in Osteoarthritis, Knee with a site in Belgium are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 383 Osteoarthritis, Knee studies recruiting now, 177 (46%) set no upper age limit and 113 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Osteoarthritis, Knee with a site in Belgium, or all of them as a file.
02

Study summary

This phase I study is a multicenter, randomized, double-blind, placebo-controlled study to assess the safety and tolerability of single ascending dose of IA 4P-004 in participants,

  • Between 18 and 80 years of age,
  • with target knee OA stage KL 2-4 A total of 32 participants will be enrolled in 4 cohorts, in each cohort participants will receive either 4P-004 or placebo (6:2).
03

Conditions studied

  • Knee Osteoarthritis

Keywords

  • OA
  • Knee OA
  • Liraglutide
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who have the capacity to give and who are willing to comply with all study related procedures and assessments (consent via legally authorized representative will not be accepted),
  • Ambulatory participants, agreeing a 24-hour hospitalization,
  • Participants between 18 and 80 years of age,
  • Female participant of (WOCBP), must use consistent with local regulations regarding the methods of contraception for those participating in clinical studies (see section 11.4) for at least 5 days following IMP injection, and must have a negative urine pregnancy test done within 24h before randomization,
  • Male participants (whose partners are of childbearing potential) must consent to use methods of contraception consistent with local regulations regarding the methods of contraception for those participating in clinical studies (see section 11.4), for at least 90 days following IMP injection,
  • Participants with knee osteoarthritis, KL 2-4 of their target knee (defined at screening as the knee with greater pain based on the participant's evaluation and the investigator's clinical judgment),
  • X-rays of the target knee within 6 months (if not, to be performed before randomization),
  • within normal range,
  • WBC (white blood cell count) > 3500/µL,
  • > 12 g/dL,
  • > 100,000/ µL,
  • (CrCl) > 60 mL/min,
  • Glycemia within normal range,
  • , ALT \< 1.5 (ULN),
  • Amylasemia \< 1ULN,
  • Negative tests for COVID-19 (if required by the standard practice on site), , HbsAg and Ab (Determination of HIV and hepatitis status can be based on participant-reported medical history, available medical records, and the most recently available laboratory results for the participant [tests performed within the previous 12 months]).

Exclusion criteria

Exclusion Criteria:

  • Breastfeeding women,
  • Treatment with systemic greater than 10 mg prednisone or the equivalent per day within 4 weeks prior to screening,
  • Any treatment with glucosamine or chondroitin sulfate in the previous 3 months,
  • Any glucagon-like peptide 1 analogue hormones,
  • Anticoagulant treatment (current or within the last 10 days),
  • Treatment of the target knee with any IA injection (steroids, hyaluronic acid derivatives, PRP ….) within 3 months,
  • Knee surgery (of the target knee) performed within the previous 12 months or planned within the next 6 months,
  • Any partial knee replacement of the target knee,
  • Any known active infections or increased predisposition for the development of infections
  • Clinical signs and symptoms of active joint crystal disease, or any inflammatory joint disease,
  • Diabetes type I or II,
  • Congestive Heart Failure stage III or IV of classification,
  • Inflammatory bowel disease,
  • Any other chronic condition that has not been well controlled for a minimum of 3 months,
  • History of of any organ system (other than localized basal cell carcinoma of the skin or in-situ cervical cancer) within the last 5 years,
  • Any condition, including laboratory findings, that in the opinion of the investigator constitutes a risk or for participation in the study or that could interfere with the study objectives, conduct or evaluation, (for example, any abnormal reaction to previous IA injection),
  • to the active substance liraglutide or to any of the : Disodium phosphate dihydrate, Propylene glycol, Phenol,
  • Participation in an interventional clinical research trial within 12 weeks prior.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    4P-004 w mg

    4P-004 is administered once intraarticularly in the target knee joint Dose = w mg

    Drug: 4P-004

  • Experimental
    4P-004 x mg

    4P-004 is administered once intraarticularly in the target knee joint Dose = x mg

    Drug: 4P-004

  • Experimental
    4P-004 y mg

    4P-004 is administered once intraarticularly in the target knee joint Dose = y mg

    Drug: 4P-004

  • Experimental
    4P-004 z mg

    4P-004 is administered once intraarticularly in the target knee joint Dose = z mg

    Drug: 4P-004

  • Placebo comparator
    Placebo

    Placebo is administered once intraarticularly in the target knee joint

    Drug: Placebo

Interventions

  • Drug4P-004

    single intraarticular administration in the knee joint

    Also known as: Liraglutide

  • DrugPlacebo

    single intraarticular administration in the knee joint

    Also known as: NaCl

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability of Single IA Administration of 4P-004 at Escalating Doses in Participants With Knee OA.

    Number of participants with Adverse Events, serious AEs (SAEs), with abnormal Vital signs, abnormal ECG reading and abnormal Laboratory test results

    Time frame: Day 1-Day 28

Secondary outcomes

  1. To Characterize the Plasma Concentration of Liraglutide When Administered as Single IA Doses at Escalating Dose Levels in Participants With Knee OA

    Plasma concentration of liraglutide following a single IA injection at pre-injection (Time \[-4hours-0\]) and 2hours, 4hours, 8hours, 12hours, 16hours and 24-hours post injection.

    Time frame: Day 1 to Day 2

Other outcomes

  1. Exploratory Biomarkers Identification

    Serum and urine OA-related biomarkers (exploratory proteomic research of 4P-004 efficacy-related biomarkers) at Day 1 (Time \[-4-0\]hours, Time 8hours), Day 2 (Time 24hours) and Day 8.

    Time frame: Day 1, Day 2, Day 8

07

Results

Posted May 15, 2025

Participant flow

Cohort 1
Participant flow — Cohort 1
Milestone4P-004 w mg4P-004 x mg4P-004 y mg4P-004 z mgPlacebo
Started60002
Completed60002
Not completed00000
Cohort 2
Participant flow — Cohort 2
Milestone4P-004 w mg4P-004 x mg4P-004 y mg4P-004 z mgPlacebo
Started06002
Completed06002
Not completed00000
Cohort 3
Participant flow — Cohort 3
Milestone4P-004 w mg4P-004 x mg4P-004 y mg4P-004 z mgPlacebo
Started00602
Completed00602
Not completed00000
Cohort 4
Participant flow — Cohort 4
Milestone4P-004 w mg4P-004 x mg4P-004 y mg4P-004 z mgPlacebo
Started00082
Completed00082
Not completed00000

Outcome measures

PrimarySafety and Tolerability of Single IA Administration of 4P-004 at Escalating Doses in Participants With Knee OA.

Number of participants with Adverse Events, serious AEs (SAEs), with abnormal Vital signs, abnormal ECG reading and abnormal Laboratory test results

Time frame:
Day 1-Day 28
Reported as:
Number · participants
Safety and Tolerability of Single IA Administration of 4P-004 at Escalating Doses in Participants With Knee OA.
participants4P-004 w mg4P-004 x mg4P-004 y mg4P-004 z mgPlacebo
TEAE55566
SAE00100
Abnormal Vital Sign00000
Abnormal Laboratory Value00000
Abnormal ECG00000
SecondaryTo Characterize the Plasma Concentration of Liraglutide When Administered as Single IA Doses at Escalating Dose Levels in Participants With Knee OA

Plasma concentration of liraglutide following a single IA injection at pre-injection (Time \[-4hours-0\]) and 2hours, 4hours, 8hours, 12hours, 16hours and 24-hours post injection.

Time frame:
Day 1 to Day 2
Reported as:
Mean · ng/mL
To Characterize the Plasma Concentration of Liraglutide When Administered as Single IA Doses at Escalating Dose Levels in Participants With Knee OA
ng/mL4P-004 w mg4P-004 x mg4P-004 y mg4P-004 z mgPlacebo
Time [-4hours-0]0 ± 00 ± 00 ± 00 ± 0—
Time 2 hours3.6 ± 1.17.2 ± 4.258.1 ± 38.824.6 ± 15.7—
Time 4 hours5.3 ± 1.813.9 ± 7.590.4 ± 58.641.6 ± 18.4—
Time 8 hours7.3 ± 3.123.2 ± 12.4123.7 ± 74.964.5 ± 23.0—
Time 12 hours7.1 ± 3.124.5 ± 12.9122.2 ± 69.267.2 ± 24.7—
Time 16 hours6.4 ± 2.923.5 ± 12.0113.6 ± 61.863.8 ± 25.4—
Time 24 hours5.0 ± 2.420.0 ± 9.495.2 ± 52.153.6 ± 25.4—
Other pre-specifiedExploratory Biomarkers Identification

Serum and urine OA-related biomarkers (exploratory proteomic research of 4P-004 efficacy-related biomarkers) at Day 1 (Time \[-4-0\]hours, Time 8hours), Day 2 (Time 24hours) and Day 8.

Time frame:
Day 1, Day 2, Day 8

Results for this outcome have not been posted.

Adverse events

Collected over For each participant, adverse events were collected from screening until the End of study (D29). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
4P-004 w mg0/6 (0%)0/6 (0%)5/6 (83.3%)
4P-004 x mg0/6 (0%)0/6 (0%)5/6 (83.3%)
4P-004 y mg0/6 (0%)1/6 (16.7%)5/6 (83.3%)
4P-004 z mg0/8 (0%)0/8 (0%)6/8 (75%)
Placebo0/8 (0%)0/8 (0%)6/8 (75%)
Most frequent serious events
Most frequent serious events
Event4P-004 w mg4P-004 x mg4P-004 y mg4P-004 z mgPlacebo
NauseaGastrointestinal disorders0/60/61/60/80/8
Most frequent other events
Showing 10 of 39
Most frequent other events
Event4P-004 w mg4P-004 x mg4P-004 y mg4P-004 z mgPlacebo
NauseaGastrointestinal disorders1/61/65/62/82/8
VomitingGastrointestinal disorders0/60/65/60/80/8
HeadacheNervous system disorders3/61/62/64/81/8
DizzinessNervous system disorders0/60/62/61/81/8
Injection site painGeneral disorders0/62/60/60/80/8
HypoglycaemiaMetabolism and nutrition disorders2/61/60/61/80/8
Abdominal distensionGastrointestinal disorders0/60/60/62/80/8
ArthralgiaMusculoskeletal and connective tissue disorders0/61/61/62/82/8
ConstipationGastrointestinal disorders0/60/61/60/80/8
Gastric dilatationGastrointestinal disorders0/60/61/60/80/8

Baseline characteristics

Age, Continuous
Age, Continuous(years)4P-004 w mg4P-004 x mg4P-004 y mg4P-004 z mgPlaceboTotal
Mean62.5 ± 6.954.2 ± 5.360.3 ± 8.559.1 ± 59.563.5 ± 11.560.1 ± 9.1
Sex: Female, Male
Sex: Female, Male(Participants)4P-004 w mg4P-004 x mg4P-004 y mg4P-004 z mgPlaceboTotal
Female3245519
Male3423315
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)4P-004 w mg4P-004 x mg4P-004 y mg4P-004 z mgPlaceboTotal
Count of participants—————0
BMI
BMI(kg/m2)4P-004 w mg4P-004 x mg4P-004 y mg4P-004 z mgPlaceboTotal
Mean29 ± 6.828 ± 5.128.5 ± 4.925.5 ± 529.5 ± 4.328.1 ± 5.1
Kellgren-Lawrence score
Kellgren-Lawrence score(Participants)4P-004 w mg4P-004 x mg4P-004 y mg4P-004 z mgPlaceboTotal
Kellgren-Lawrence 22436621
Kellgren-Lawrence 34131211
Kellgren-Lawrence 4010102
NRS
NRS(units on a scale)4P-004 w mg4P-004 x mg4P-004 y mg4P-004 z mgPlaceboTotal
Mean3.8 ± 2.34.0 ± 2.03.5 ± 2.63.5 ± 2.33.7 ± 2.43.7 ± 2.2
08

Study locations

3 sites
  • UCL-St Luc
    Brussels, 1200, Belgium
  • AZMaria Middelares
    Ghent, 9000, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
09

References and documents

Publications

  • Meurot C, Martin C, Sudre L, Breton J, Bougault C, Rattenbach R, Bismuth K, Jacques C, Berenbaum F. Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis. Sci Rep. 2022 Jan 28;12(1):1567. doi: 10.1038/s41598-022-05323-7. PubMed 35091584 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Oct 2023, 14 months.

Results were first posted in May 2025, 1 year 6 months after primary completion.

Of 34 industry-sponsored phase 1 interventional studies under Osteoarthritis, Knee, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 21. This study's 14 months is close to that.

Counting every sponsor, half of 61 studies reached it within 20 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2022
First posted
Jun 15, 2022
StartActual
Aug 9, 2022
Primary completionActual
Oct 31, 2023
CompletionActual
Oct 31, 2023
Results first posted
May 15, 2025
Last update
Jun 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05419856
Lead sponsor
4Moving Biotech
Responsible party
Sponsor
First posted
Jun 15, 2022
Start date
Aug 9, 2022
Primary completion
Oct 31, 2023
Completion
Oct 31, 2023
Results posted
May 15, 2025
Last update
Jun 26, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liraglutide

Start the discussion